Why the study?
Influenza vaccine efficacy is limited by antigenic variation and does not affect other influenza-like illness viruses, prompting the need for additional immunostimulatory options for prevention and treatment.
Answers are grounded in this paper and cite their sources.
The article reviews options for preventing and treating influenza-like illness, primarily focusing on immune system support.
ChĹipka je v souÄasnosti Ĺazena do ĹĄirĹĄĂ skupiny oznaÄovanĂŠ jako chĹipkovitĂĄ onemocnÄnĂ (influenza-like illness, ILI). Jde o skupinu virovĂ˝ch zĂĄnÄtĹŻ hornĂch dĂ˝chacĂch cest, kterĂŠ se mohou (podle individuĂĄlnĂ reaktivity) projevovat obdobnĂ˝m klinickĂ˝m obrazem jako pravĂĄ chĹipka ("chĹipkovĂ˝ syndrom" - pĹedevĹĄĂm vysokĂĄ teplota, kaĹĄel, bolest v krku). Tyto pĹĂznaky mĹŻĹže vyvolat kromÄ viru chĹipky takĂŠ celĂĄ Ĺada dalĹĄĂch virĹŻ. LĂŠÄba tÄchto onemocnÄnĂ (kromÄ antivirotik, kterĂĄ lze uĹžĂt u "pravĂŠ" chĹipky) je symptomatickĂĄ. V prevenci, ale i lĂŠÄbÄ chĹipkovitĂ˝ch onemocnÄnĂ hraje zĂĄsadnĂ roli posilovĂĄnĂ imunity. KlasickĂ˝m prostĹedkem imunostimulace proti chĹipce je vakcinace. ĂÄinnost vakcĂn je vĹĄak omezenĂĄ kvĹŻli antigennĂm zmÄnĂĄm chĹipkovĂŠho viru, navĂc vakcĂna neovlivĹuje vĂ˝skyt jinĂ˝ch virovĂ˝ch onemocnÄnĂ tĂŠto skupiny. Proto je vhodnĂŠ vyuĹžĂvat dalĹĄĂch moĹžnostĂ imunostimulaÄnĂ prevence chĹipkovitĂ˝ch onemocnÄnĂ. ÄlĂĄnek se vÄnuje nÄkterĂ˝m moĹžnostem prevence a lĂŠÄby tĂŠto skupiny chorob, zaloĹženĂ˝m pĹedevĹĄĂm na podpoĹe imunitnĂho systĂŠmu.
No takes yet. Share an insight, caveat, or question.
Boženský et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: